Lumosa Therapeutics' LT3001 Shows Promise in Phase II Acute Ischemic Stroke Trial
Lumosa Therapeutics' LT3001 demonstrated a robust safety profile and tolerability in a Phase II clinical trial for acute ischemic stroke patients.
© Copyright 2025. All Rights Reserved by MedPath